Bio-Thera Solutions (688177:SH), a China-based commercial-stage biopharmaceutical company, announced on Monday that it has received IND approval from the US FDA for a phase II study of BAT8006, an innovative Antibody Drug Conjugate (ADC) targeting Folate Receptor alpha (FR alpha).
The phase II study is to assess the use of BAT8006 for the treatment of subjects with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
BAT8006 has been developed utilising Bio-Thera's proprietary anti-FR alpha antibody and proprietary ADC linker-payload combination that comprises of a systemically stable and cleavable linker and a small molecule topoisomerase I inhibitor. The company says that preclinical studies have shown that BAT8006 demonstrates good stability and safety along with strong anti-tumour activity.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI